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Combination antiretroviral therapy during primary human
immunodeﬁciency virus-1 infection may enable long-term
drug-free virological control in rare individuals. We describe
a female who maintained aviremia and a normal CD4+/CD8+
T cell ratio for 10 years after stopping therapy, despite a per-
sistent viral reservoir. Cellular immune responses may have
contributed to this outcome.
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Achieving prolonged control of human immunodeﬁciency
virus (HIV)-1 replication after antiretroviral therapy (ART)
interruption is one of the aims of present research efforts to-
wards eradication, to alleviate HIV-1 burden, drug toxicity,
and costs. Initiation of ART during primary HIV-1 infection
(PHI) is associated with reduced size and diversity of viral res-
ervoirs and enhanced immune preservation, relative to chronic
infection. This is reﬂected in prolonged aviremia in a minority
of early treated seroconverters who discontinue ART [1–3].Elu-
cidating the underlying mechanisms may facilitate the develop-
ment of curative therapy. In this study, we describe the favorable
outcome of a woman who initiated ART during a severe acute
retroviral syndrome. She stopped therapy 6 years later and has
since experienced a decade of apparent spontaneous control.
We report the virological and immunological features of this
unusual case.
METHODS
Quantiﬁcation of the Human Immunodeﬁciency Virus-1
Reservoir
Written permission was obtained from the patient for reporting
of her case. The patient was infected with a clade C virus. During
17 years of follow-up, HIV-1 viremia was quantiﬁed with several
validated assays, which included non-B primers in accordance
with laboratory and clinical practice at the time. Low copy vire-
mia was determined as described in Supplementary Methods.
Quantiﬁcation of cell-associated HIV-1 DNA in blood sampled
during 2007–2013 was performed as described previously [4, 5].
Integrated HIV-1 DNA was determined in samples from 2013
onwards by Alu-HIV polymerase chain reaction (PCR), in addi-
tion to quantiﬁcation of total and episomal 2-long terminal
repeat (LTR) circles [6, 7] (Supplementary Methods).
Human Leukocyte Antigen Typing
The patient’s human leukocyte antigen (HLA) type was deter-
mined by ARMS-PCR using sequence-speciﬁc primers as fol-
lows: HLA A*0101, *3001, B*4901, Cw*0701, DRB1 *0804,
DQB1 *0301 (homozygous at HLA-B, Cw, DR, and DQ loci).
Assessment of Human Immunodeﬁciency Virus-1-Speciﬁc
Cellular Immune Responses
T-cell responses to the entire HIV-1 proteome were assessed
initially using pools of clade B 15-mer peptides overlapping
by 11 amino acids and, subsequently, corresponding over-
lapping clade C 18-mers, (NIH AIDS Reagent Program, ﬁnal
concentration 2 µg/mL) in ex vivo interferon (IFN)-γ enzyme-
linked immunospot (ELISPOT) assays, as described previously
[8]. Further details are given in Supplementary Methods.
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Figure 1. CD4 cell count and plasma viral load changes (A), CD4/CD8 cell ratios, and percentage of activated (CD38+) CD8 T cells (B) during primary
infection, antiretroviral therapy, and posttreatment discontinuation are shown. Antiretroviral therapy regimen: nucleoside reverse-transcriptase inhibitors
zidovudine/lamivudine days 12–2121 and tenofovir/lamuvidine days 2122–2289; protease inhibitors indinavir days 12–22, ritonavir (full dose) days 23–203,
and ritonavir/saquinivir days 204–2289. The assays used to quantify human immunodeﬁciency virus (HIV)-1 RNA were as follows, in chronological order:
Roche Amplicor HIV-1 Monitor version 1.0 assay with non-clade B primers added (ﬁrst 2 samples in 1997); Roche COBAS Amplicor HIV-1 Monitor, replaced
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Unfractionated and CD8+-depleted peripheral blood mononu-
clear cells (PBMCs) were also tested in IFN-γ ELISPOT assays
with pools of peptides representing “beneﬁcial regions” that are
preferentially targeted by individuals with reduced viral loads
[9] (Supplementary Table 1).
Ex vivo CD8+ T-cell viral inhibitory activity was determined
using a viral inhibition assay as described previously [8]. Prima-
ry CD4+ T cells were superinfected with laboratory-adapted or
primary virus isolates (Programme EVA Centre for AIDS Re-
agents, National Institute for Biological Standards and Control)
at a multiplicity of infection of 0.01: HIV-1BaL (CCR5-tropic,
clade B), HIV-1IIIB (CXCR4-tropic, clade B), and HIV-1C
(CCR5-tropic, clade C).
RESULTS
Case Report
A 23-year-old woman of Ethiopian origin presented in 1997
with a 3-week history of fever, sore throat, rash, lymphadenop-
athy, myalgia, and arthralgia. Her HIV-1 antibody test was pos-
itive with incomplete reactivity on HIV Western blot. She had
tested HIV-1 seronegative in 1996. Three consecutive CD4+ T-
cell counts were <200 cells/mm3, and her viral load was initially
>750 000 HIV-1 copies (c)/mL. The patient started zidovudine
250 mg twice daily, lamivudine 150 mg twice daily, and indin-
avir 800 mg 3 times a day. The latter was subsequently switched
to ritonavir 600 mg twice daily because of intolerance. She re-
mained viremic (up to 94 400 HIV-1 c/mL) while on treatment
and required intensiﬁcation (twice daily saquinavir 400 mg and
ritonavir 400 mg), which was initiated in May 1998. Suppres-
sion of viremia <50 HIV-1 c/mL was not achieved until approx-
imately 1 year later, but it was sustained for nearly 5 years
thereafter, at which point ART was stopped at the patient’s re-
quest. The pre-ART discontinuation CD4+ T-cell count was
863 cells/mm3 (30%), with a CD4+/CD8+ T-cell ratio of 0.7.
The patient has since remained asymptomatic with undetect-
able viremia, normal CD4+ T-cell counts, and a CD4+/CD8+
T-cell ratio >1 during 10 years of follow-up off ART (Figure 1).
A comprehensive screen for antiviral agents by therapeutic drug
monitoring on a blood sample from 2008 was negative (Delphic
Laboratories Ltd, Merseybio Liverpool, UK). Furthermore, the
frequency of activated (CD38+) CD8+ T cells, which was mea-
sured during 2004–2010, remained within normal limits (3%–
21%) (Figure 1B). Human leukocyte antigen typing revealed
that the patient did not express any HLA class I alleles associ-
ated with long-term control of HIV.
Evidence of a Detectable Human Immunodeﬁciency Virus-1
Reservoir During Posttreatment Control
During the posttreatment period with aviremia, HIV-1 DNA
was detected on 4 occasions: 2004 (not quantiﬁed), 2007,
2013, and 2014. Total HIV-1 DNA was 285, 619, and 149 cop-
ies/106 PBMCs in 2007, 2013, and 2014, respectively. At 15
years of aviremia (2014), integrated HIV-1 DNA and 2-LTR cir-
cles were 134.3 (95% conﬁdence interval [CI], 56.5–304.4) and
3.9 (95% CI, 0–9.15) copies/106 PBMCs, respectively (Fig-
ure 1A). Viremia was undetectable by an ultrasensitive assay
(<2 HIV-1 copies/mL).
CD8+ T Cells Sampled After 10 Years of Posttreatment Control
Suppress Human Immunodeﬁciency Virus-1 Replication In Vitro
Ex vivo CD8+ T cells were tested for their capacity to inhibit the
replication of clade B and C HIV-1 isolates and of endogenous
HIV-1 in autologous CD4+ T cells in vitro. At a CD8+/CD4+
ratio of 1:1, CD8+ T cells demonstrated moderate antiviral ac-
tivity against clade-matched (C, 73.5%) and mismatched (IIIB,
73.3%; BaL, 49%) virus isolates (Figure 1C and D). Efﬁcient
suppression of the clade C isolate was also observed at a lower
CD8+/CD4+ T-cell ratio (1:10%–59% vs 30% for IIIB and 22%
for BaL). Antiviral activity against the patient’s endogenous
virus was equivalent to HIV-1C at both CD8+/CD4+ T cell ra-
tios (70.5% and 52.3% for 1:1 and 1:10 ratios, respectively) (Fig-
ure 1C and D).
Broad CD4+ T-Cell Responses Target Vulnerable Regions Within
Gag
Interferon-γ-secreting CD8+ and CD4+ T cells were predomi-
nantly targeted to 14 regions within HIV-1 Gag, Pol, and Nef
(Figure 1E, Supplementary Figure 1A–C). T-cell responses
were also targeted to 7 vulnerable (beneﬁcial) regions within
the clade B and C viral proteomes (Supplementary Table 1)
and were predominantly CD4+ T cell-mediated (Figure 1E
and 1F, Supplementary Figure 1D).
Figure 1 continued. by version 1.5 (Ultrasensitive assay) in October 2004; Abbott LCx HIV-1 assay (January 2005–May 2005); Abbott Real-Time HIV-1
assay (May 2005 onwards). Antiretroviral agents included in therapeutic drug monitoring in 2008 were as follows: lamivudine, efavirenz, atazanavir,
amprenavir, indinavir, nelﬁnavir, lopinavir, ritonavir, saquinavir, darunavir, tipranavir. (C) Susceptibility of the patient’s CD4+ T cells to superinfection
with clade (B) and (C) virus isolates and to induction of endogenous HIV-1: frequencies of p24 Ag+ CD4+ T cells after in vitro activation of CD8-depleted
peripheral blood mononuclear cells (PBMCs), followed by superinfection and culture for 6 days, or culture without superinfection (autologous virus) for up to
11 days. (D) Inhibition of replication of superinfecting or autologous viruses by patient’s CD8+ T cells after 6 days’ coculture at CD8/CD4 cell ratios indicated.
(E) Responses to individual clade C consensus Gag peptides identiﬁed in the peptide matrix assays were conﬁrmed by interferon (IFN)-γ enzyme-linked
immunospot (ELISPOT) assays with unfractionated PBMCs. Negative control values have been subtracted. Some of these peptides overlapped “beneﬁcial”
regions within clade B and C Gag that were previously associated with virological control—shown in bold [9]. (F) CD4+ T-cell responses to peptides rep-
resenting beneﬁcial regions within clade B/C Gag (listed in Supplementary Table 1) were determined in IFN-γ ELISPOT assays with CD8-depleted PBMCs.
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DISCUSSION
This case shows that long-term control of viremia and normal-
ization of immune parameters may follow discontinuation of
prolonged ART initiated at PHI, even in the context of persis-
tent viremia of nearly 5 log10 HIV-1 c/mL during initial ART
and the absence of favorable HLA alleles. Such features would
typically preclude long-term nonprogressor status [10].
Salgado et al and Sáez-Cirión et al have reported post-ART
virological control after treatment during PHI, despite initial vi-
remia of up to 7 log10 c/mL. The majority of these subjects had
an inducible viral reservoir, indicating that they were infected
with replication-competent viruses [2, 3]. We conﬁrmed that
our patient’s CD4+ T cells were susceptible to superinfection
with R5- and X4-tropic viruses, with similar frequencies of in-
fected cells to those we have observed following in vitro infection
of healthy donor PBMCs [11]. Furthermore, we were able to
detect outgrowth of endogenous HIV-1 in CD4+ T cells after
in vitro activation, albeit at a low level, indicating a persistent in-
ducible reservoir. Although posttreatment controllers thus show
some virological similarities with patients with spontaneous elite
control of HIV-1, an intriguing difference is the lower activation
status in the former [12]. Our patient also showed posttreatment
control of immune activation: the frequency of CD38+ CD8+
T cells has remained within normal limits throughout follow up.
With regard to HIV-speciﬁc immune responses, this case is
distinct from previously described posttreatment controllers [2,
3]. CD8+ T-cell inhibition of both heterologous and autologous
HIV-1 replication was detected at a low CD8+/CD4+ cell ratio.
Although these responses were less potent than was observed in
HIV controllers (median 85%, n = 20) [8, 13], they nevertheless
surpassed that of chronic ART-treated individuals who were vi-
rologically suppressed for ≥1 year (median 24%, n = 42; our un-
published observations). This result suggests that our patient’s
CD8+ T-cell antiviral responses were likely to be a contributing
factor to her virological control, rather than a consequence of it.
The preserved and broad HIV-1-speciﬁc CD4+ T-cell responses
observed in this patient are also particularly surprising when
taking into account the profound CD4+ T-cell depletion ob-
served before ART initiation. It is noteworthy that this patient
had detectable CD4+ T cell responses (polyfunctional and
proliferative) in 2004 and 2008 (Supplementary Figures 2–4).
Furthermore, we were able to show that CD4+ T cells were
targeted to multiple regions of vulnerability within Gag. Such
responses have been associated with spontaneous control of
viremia [9, 14]. It is not known whether this association is me-
diated by direct cytolytic mechanisms or indirectly, through
provision of effective help to CD8+ T cells. This deserves further
exploration. We also considered the possibility that humoral re-
sponses contributed to this patient’s posttreatment control, be-
cause broadly neutralizing antibodies may play a role in
controlling viremia in rare cases [15]. However, we found
only low levels of neutralizing antibodies to heterologous
virus in this case, when tested during the early period of avire-
mia in 2006–2007 (data not shown).
CONCLUSIONS
In conclusion, we have identiﬁed an atypical case of posttreat-
ment control, which may have been achieved through very early
ART during PHI combined with effective cell-mediated im-
mune responses. Our data suggest that strategies aiming to in-
duce such immune responses during early ART might inﬂuence
posttreatment virological control.
Supplementary Material
Supplementary material is available online at Open Forum Infectious
Diseases (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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